<DOC>
	<DOCNO>NCT00270504</DOCNO>
	<brief_summary>The purpose study evaluate placement temporary urethral stent 12 month , follow dilation internal urethrotomy ( cut open ) , result higher rate urethral patency first year follow-up compare control group receive stent .</brief_summary>
	<brief_title>MemokathÂ® 044TW Stent Treatment Urethral Stricture</brief_title>
	<detailed_description>Patients bulbar urethral stricture 2:1 randomise either urethral dilation internal urethrotomy ( treatment group ) without ( control group ) subsequent stenting . All patient follow one year 4-6 week , 3 , 6 , 9 12 month visual assessment ( urethroscopy ) urethral patency treat segment urethra . The stent remove one year . In case premature stent removal patient also follow one year unless intervention decide . Control patient offer stent treatment option stricture recurs within observation period group separately analyse .</detailed_description>
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Urethral Stricture</mesh_term>
	<criteria>1 . Males &gt; 21 year age 2 . Recurrent stricture bulbar urethra : 1 . &lt; 50 mm length urethrography ; 2. segment unable accommodate 16Fr flexible cystoscope 3 . Healthy tissue side stent 4 . Urinary flow abnormal range Siroky nomogram . 5 . Written inform consent obtain prior participation study 6 . Patients must available followup visit . 1 . Strictures : 1. outside bulbous urethra 2. associate , suspect , urethral carcinoma 3. secondary pelvic distraction injury 2 . Inability enlarge bulbar urethral stricture &gt; 26 Fr . 3 . Presence urologic implant 4 . Presence urethral diverticuli 5 . History hypospadias repair 6 . Presence prior history balanitis xerotica obliterans . 7 . Uncontrolled bleed disorder 8 . Active urinary tract infection 9 . Any urological condition would likely require additional urethral instrumentation period investigation , include , limited , benign prostatic hypertrophy require treatment ; use alpha blocker ; active prostate cancer ; unevaluated elevate prostatespecific antigen ( PSA ) ; bladder malignancy ; recurrent urinary stone formation . 10 . Serum creatinine &gt; 2.0 mg/dl evidence progressive renal disease 11 . Concurrent participation another clinical investigation 12 . Current illness might confound result investigation 13 . Inability participate necessary study activity 14 . Inability unwillingness return require followup visit 15 . Inability unwillingness sign patient inform consent document</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Memokath</keyword>
	<keyword>Urethral stricture</keyword>
	<keyword>urethral stent</keyword>
	<keyword>Bulbar urethral stricture</keyword>
</DOC>